C12N 2310/30
Chemical structure
C12N2310/30 (Chemical structure) appears on 6,708 US grants and 12,170 published applications in this corpus.
Search patents in C12N- Granted patents
- 6,708
- Published applications
- 12,170
- Assignees
- 2,431
- Inventors
- 13,127
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 5 | 0 |
| 1993 | 12 | 0 |
| 1994 | 8 | 0 |
| 1995 | 18 | 0 |
| 1996 | 46 | 0 |
| 1997 | 123 | 0 |
| 1998 | 131 | 0 |
| 1999 | 147 | 0 |
| 2000 | 174 | 0 |
| 2001 | 154 | 23 |
| 2002 | 150 | 118 |
| 2003 | 89 | 410 |
| 2004 | 78 | 413 |
| 2005 | 50 | 344 |
| 2006 | 63 | 236 |
| 2007 | 61 | 212 |
| 2008 | 60 | 177 |
| 2009 | 96 | 315 |
| 2010 | 161 | 305 |
| 2011 | 181 | 340 |
| 2012 | 200 | 328 |
| 2013 | 199 | 327 |
| 2014 | 242 | 384 |
| 2015 | 322 | 517 |
| 2016 | 325 | 595 |
| 2017 | 347 | 520 |
| 2018 | 362 | 587 |
| 2019 | 409 | 623 |
| 2020 | 395 | 647 |
| 2021 | 396 | 739 |
| 2022 | 386 | 773 |
| 2023 | 336 | 856 |
| 2024 | 370 | 918 |
| 2025 | 348 | 863 |
| 2026 | 262 | 600 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- CAS12B enzymes and systems6 Oct 2026US 12,753,406 B2Massachusetts Institute of Technology
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Modified guide rnas8 Oct 2026US 2026/0308577 A1Genentech, Inc.
- Optimized gapmers antisense oligonucleotides for increasing foxg1 expression8 Oct 2026US 2026/0308582 A1EliGab Tx LLC
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)8 Oct 2026US 2026/0308585 A1Alnylam Pharmaceuticals, Inc.
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Methods for identifying nucleic acid ligands856US 5,270,163 AUniversity Research Corporation · 1993
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Peptide nucleic acids763US 5,539,082 A1996